• 정신신체의학
• /
• 제28권1호
• /
• pp.81-88
• /
• 2020

연구목적 이 연구는 심박변이도(Heart rate variability, HRV) 지표를 이용하여, 불안장애, 우울장애, 외상 및 스트레스 관련 장애의 차이를 비교하고 증상 심각도와의 연관성을 보고자 한다. 방 법 2017년부터 2018년까지 국립정신건강센터 스트레스 클리닉 내원 환자의 후향적 의무기록을 분석하였다. 총 473명 환자(불안장애 166명, 우울장애 184명, 외상 및 스트레스 관련 장애 123명)의 HRV 지표의 진단 군간 차이를 비교하였다. 또한 지표와 전반적 임상 인상 심각도(Clinical Global Impression-Severity Scale, CGI-S)의 연관성이 진단군에 따른 차이를 보이는지 분석하였다. 결 과 세 군에서 HRV 지표는 유의한 차이를 보이지 않았다. 그러나, 심박도 간격(normal-to-normal, NN)의 표준 편차(standard deviation of normal RR intervals, SDNN)와 연속된 NN 간격들의 변이의 제곱 평균값의 루트 값(the square root of the mean squared differences of successive NN intervals, RMSSD)의 CGI-S와의 관련성은 그룹 간 유의한 차이가 나타났다(SDNN, p=0.017 ; RMSSD, p=0.034). 불안장애와 우울장애에서는 CGI-S에 따른 SDNN, RMSSD가 음의 관련성을 보였지만, 외상 및 스트레스 관련 장애에서는 양의 관련성을 보였다. 결 론 본 연구에서 세 군의 HRV 지표는 차이를 보이지 않았지만, 각 군에서 지표와 임상적 심각도와의 연관성은 다른 양상을 보였다. 본 연구 결과는 외상 및 스트레스 관련 장애군은 HRV의 특징 및 임상적 활용이 불안 및 우울장애와 다를 수 있음을 시사한다.

• 턱관절균형의학회지
• /
• 제6권1호
• /
• pp.24-26
• /
• 2016

경추부 근긴장 이상증에 대해 턱관절 자세균형 개념에 따라 구강내 균형장치를 활용한 자세훈련법 등의 치료로 긍정적인 호전을 관찰했다. 증례 보고이기는 하지만 턱관절 자세균형을 활용한 치료법에서 긍정적인 치료효과가 이어지고 있어서 앞으로 더욱 체계적인 관찰과 연구가 필요할 것으로 사료된다.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제16권2호
• /
• pp.279-285
• /
• 2005

목적 : 이 연구에서는 장시간 약물작용이 지속되는 MPH-OROS를 주의력결핍과잉운동장애 아동에게 투여하여 그 효용성과 안전성 및 부모 만족도를 평가하려고 하였다. 방법 : 연구대상은 DSM-IV의 진단기준을 이용하여 임상적으로 ADHD로 진단 받은 569명의 아동으로 하였다. 이미 약물을 복용중이거나 약을 복용한 적이 없는 아동을 대상으로 이전 약물에서 MPH-OROS로 약물을 바꾸거나 처음으로 MPH-OROS를 복용하였다. 증상의 정도는 MPH-OROS 약물 사용 전과 사용 1주 및 3주에 한국어판 Conners 부모용 평가척도를 사용하여 평가하였다. 임상 호전은 Clinical Global Impression Severity of illness(CGI-S)를 사용하여 MPH-OROS 약물 복용 전과 복용 1주 및 3주에 임상가가 평가하였고 Clinical global impression severity of improvement(CGI-I)로 약물 복용 1주 및 3주에 호전 정도를 평가하였다. 약물 복용 3주에는 약물 복용에 따른 부모 만족도를 설문 조사하였다. 결과 : MPH-OROS의 1일 평균 복용량은 기저선 $25.3{\pm}11.2mg$ 1주 $28.9{\pm}12.7mg$, 3주 $31.3{\pm}13.2mg$이었다. 시간에 따라 용량이 유의하게 증가하였고, 성에 따른 차이는 없었다. 전체의 $13\%$가 중도 탈락했으며, 그 원인으로는 부작용이 가장 많았다. CGI-I의 변화는 시간에 따라 유의하게 감소하는 모습을 보였고, 성에 따른 호전 정도의 차이는 나타나지 않았다. CGI-I에 의한 호전평가에서 MPH-OROS 치료 1주에 호전은 $72.3\%$이고 치료 3주에는 $87.4\%$였다. 한국판 Conners부모용 평가척도 합계 점수는 시간에 따라 유의하게 감소하였다. 한 가지 이상의 부작용을 경험하였던 환자는 119명으로 $20.7\%$에 달하였으며, 가장 많은 빈도로 나타난 것은 식욕부진이고, 불면, 두통, 오심의 순이었다. 기존에 속효성 메틸페니데이트를 사용하던 군과 약물을 처음 사용하는 군을 나누어 부작용 빈도를 살펴보았을 때 크게 차이가 나지 않았다. 부모만족도 설문 결과에서 MPH-OROS 약물치료에 대해 $94\%$의 부모는 전반적으로 만족한다고 응답하였다. 또한 부모가 보고하는 MPH-OROS 의 가장 큰 장점은 오후까지 약물효과 지속, 학교생활 및 수업태도, 가정생활 및 숙제, 과잉행동 개선의 순이었다. 결론 : MPH-OROS는 주의력결핍과잉운동장애의 치료에서 효과적이며 충분히 안전하다.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제19권3호
• /
• pp.147-155
• /
• 2008

Objectives: The purpose of this study was to evaluate the efficacy and tolerability of osmotic release oral system-methylphenidate (OROS-MPH) in children with attention-deficit hyperactivity disorder (ADHD) and comorbid psychiatric disorders. Methods: This was an 8-week open label study of OROS-MPH monotherapy. The subjects were 113 children with ADHD aged 6-12 years. Outcome measures were the Korean version of the parent ADHD Rating Scale (K-ARS), Korean version of the Conners Parent Rating Scale (K-CPRS), Clinical Global Impression-Severity and Clinical Global Impression-Improvement. Side effects were monitored using Barkley's Side Effect Rating Scale. We compared the change-over-time in the mean scores of the outcome measure according to the comorbidity of disruptive behavior disorder, depressive disorder, anxiety disorder, and tic disorder. Results: The mean K-ARS and K-CPRS scores were significantly decreased, regardless of the comorbidity. The mean doses of OROS-MPH and dropout rate did not differ significantly according to comorbidity. The OROS-MPH was well tolerated, regardless of the comorbidity. However, children with tic disorder reported a higher frequency of tics or nervous movements between the $2^{nd}\;and\;8^{th}$ week than those without tic disorder. Conclusion: The OROS-MPH is effective for decreasing the symptoms of ADHD, and it is well tolerated, even by patients with comorbid psychiatric disorders.

• Journal of Acupuncture Research
• /
• 제39권3호
• /
• pp.202-212
• /
• 2022

Background: The aim of this study was to evaluate the effectiveness and safety of Cheong-A-Won Gagambang (JCE003) treatment for degenerative knee osteoarthritis. Methods: This was a single-center, randomized, double-blind, placebo-controlled pilot clinical trial. There were 36 adults with degenerative knee osteoarthritis who were randomly allocated into JCE003 1,000 mg, JCE003 2,000 mg, or the placebo group (in a 1:1:1 ratio). The participants received 12 weeks of treatment and had scheduled tests every 6 weeks. The primary outcomes were measured using the Korean Western Ontario and McMaster Universities scale, and the secondary outcomes were measured using the visual analog scale, European quality of life-5-dimensions, patient global impression of change, C-reactive protein, and erythrocyte sedimentation rate. Changes between baseline scores and scores following study completion were analyzed. Results: There were 29 participants whose data were analyzed in this study. The change of Korean Western Ontario and McMaster Universities, visual analog scale, European quality of life-5-dimensions scores showed significant improvement in the JCE003 1,000 mg group. The change of patient global impression of change was significantly improved in the placebo group. There were 14 adverse events, but there was no clinically significant relationship with the intake of JCE003 compared with the placebo. Conclusion: Taking JCE003 may be effective at improving knee pain in patients with degenerative knee osteoarthritis and appears to be safe. Based on this study, the concentration and feasibility of the test group may be used when conducting a large-scale clinical trial of degenerative knee osteoarthritis in the future.

• 생물정신의학
• /
• 제23권2호
• /
• pp.41-47
• /
• 2016

Dementia with Lewy bodies (DLB) is the second most common causes of dementia. It can exhibit a variety of clinical symptoms including cognitive decline, cognitive fluctuation, visual hallucinations, parkinsonism, REM sleep behavior disorder, hypersensitivity to neuroleptics and autonomic dysfunctions. Despite more well-known criteria for DLB, there are often misdiagnosis and inappropriate treatment. It gives a lot of clinical burden to the clinician as well as to patients and families. When reducing the misdiagnosis, the burden of all will be reduced. The special concern and solicitation are needed in order not to miss the diagnosis when the cardinal features of DLB may not be volunteered by patients and the caregivers. To control the symptoms, clinicians must find and reduce drugs that can have the negative effects on DLB symptoms. There is limited evidence about specific interventions but available data suggest cholinesterase inhibitors improve the cognitive and behavioral symptoms and menmantine slightly improves the global impression.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제26권4호
• /
• pp.273-278
• /
• 2015

Objectives : We retrospectively investigated the efficacy and tolerability of risperidone monotherapy in subjects with autism spectrum disorder (ASD). In addition, we did mixed effect model analysis of the effects of risperidone in patients with ASDs naturalistically treated in a routine clinical setting to determine whether the clinical effects were maintained and the side effects were tolerable. Methods : This retrospective study assessed children and adolescents with ASD, who were on risperidone monotherapy from July 2010 to July 2011 at the Child and Adolescent ASD Clinic at Seoul National Hospital. Outcome measures included the Clinical Global Impression-Severity of Illness (CGI-S) and the CGI-Improvement (CGI-I) scales along with other clinical indices: dosage, target symptoms, and side effects. Results : The mean dose of risperidone in 47 children and adolescents with ASD (40 males, 7 females; age range 5-19 years) who were on risperidone monotherapy was $1.6{\pm}0.8mg/day$, and the mean duration of the treatment period was $20.2{\pm}17.3months$. Aggressive behavior, stereotypic behavior, irritability, and self-injurious behavior were the most frequent target symptoms of risperidone. The most common side effects were weight gain followed by somnolence and extrapyramidal symptoms. In a mixed effects model analysis of CGI-I scores, the mean CGI-I score at the 1 month follow-up was significantly different from the mean CGI-I score of the 3-month follow-up (p=.046), and the CGI-I scores were equally maintained over 3 to 48 months [F(6, 28.9)=4.393, p=.003]. Of the 47 patients, 33 patients (70.2%) were identified as the response group, showing an end point CGI-I rating of 3 or under and having continued risperidone treatment for at least 6 months. The baseline CGI-S score showed significant association with clinical response to risperidone (p=.005), the mean baseline CGI-S was higher in the response group compared to the non-response group. Conclusion : In this study, clinical improvement of risperidone stabilized around 3 months and was equally maintained up to 48 months with tolerable side effects, supporting maintenance of risperidone treatment in children and adolescents with ASDs.

• Clinical Pain
• /
• 제20권2호
• /
• pp.105-121
• /
• 2021

Objective: Physiologically, the vastus medialis muscle is the first muscle to undergo muscle atrophy, and it was thought that pain in patients with knee osteoarthritis could be reduced if this muscle could be strengthened and stabilized. The purpose of this study was to prove the effectiveness in knee osteoarthritis using polydioxanone sutures that have been tried in other musculoskeletal areas. Method: Forty knee osteoarthritis patients voluntarily participated in the study, and divided into 30 polydioxanone suture needle (MEST-B2375 produced by Ovmedi Co.) and 10 sham needle (without suture). And the needles were inserted into the vastus medialis muscle. In all patients, safety evaluation including blood tests and ultrasonography as well as efficacy evaluation including isometric maximal contractile strength of quadriceps muscle, weight bearing pain, impression of change, quadriceps angle, rescue drug intake were evaluated up to 30 weeks after the procedure. Results: Isometric maximal contractile strength showed a significant improvement at 4 weeks after the procedure in the polydioxanone suture group, and the weight-bearing pain showed a significant improvement at every visit in the polydioxanone suture group compared with baseline values. Patient global impression of change score showed significant improvement at 20 and 30 weeks, and clinical score showed improvement at every visit. Conclusion: Insertion of polydioxanone sutures showed improvement in muscle strength and knee pain by supporting and fixation of the vastus medialis muscle in patients with degenerative knee osteoarthritis. Insertion of polydioxanone sutures is considered to have a therapeutic effect in knee osteoarthritis patients.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• 제8권2호
• /
• pp.266-272
• /
• 1997

본 연구의 목적은 선택적 함구증 환자에게 강력한 세로토닌 재흡수 억제제인 fluoxetine을 투여한 후에 임상효과를 검증하고자 하였다. 대상은 선택적 함구증 환아 17명으로 8주간 fluoxetine $20{\sim}60mg$을 투약하였고, Clinical Global Impression(CGI), Children’s Depression Inventory(CDI), Revised Children’s Manifest Anxiety Scale(RCMAS) 척도의 변화를 통해 치료효과를 평가함과 아울러 선택적 함구증의 동반병리 및 fluoxetine의 부작용을 조사하였다. Fluoxetine 치료후의 CGI 척도 점수는 치료전의 4.3(${\pm}0.6$)점에서 1.9(${\pm}0.9$)점으로, CDI는 치료전 17.8(${\pm}5.6$)점에서 11.6(${\pm}3.9$)점으로, RCMAS는 치료전 13.2(${\pm}4.2$)점에서 9.6(${\pm}3.6$)점으로 유의한 감소를 보였고, 8주 치료기간 중 치료 4주 이후에 58.8%의 환자가, 치료 8주 시기에는 76.5%의 환자가 임상적 호전을 보고하였다. 선택적 함구증 환자들은 가족 관계의 문제, 사회공포증, 경계성 지능, 언어문제 등의 정신과적 질환이 동반되어 있었으며, 8주간의 fluoxetine투여기간동안 식욕감퇴, 흥분/탈억제, 입면곤란, 구역질, 입마름 등의 부작용이 나타났으나 대체로 내약성을 유지하였다. 이 연구를 통해서 선택적 함구증 환아의 치료에 선택적 세로토닌 재흡수 억제제가 효과적임이 시사된다.

• 생물정신의학
• /
• 제8권1호
• /
• pp.140-146
• /
• 2001

In clinical setting, treatment-refractoriness, medication induced tardive dyskinesia and amenorrhea in chronic schizophrenia are frequently problematic. However, there are few guideline solving these problem available to clinicians. The goal of this study was collecting clinical data on clinical effectiveness and predictors of response of switching to olanzapine. We attempted to switch to olanzapine from risperidone and clozapine in chronic 31(risperidone 17, clozapine 14) schizophrenia and schizoaffective disorder patients suffering from sustained symptoms, weekly blood monitoring, medication induced tardive dyskinesia and amenorrhea. Previous antipsychotics dosage was gradually decreased for 2 or 3weeks, at the same time olanzapine dosage was gradually increased. At baseline, after 1 week, after 2 weeks and after 4 weeks we checked Brief Psychiatric Rating Scale, Clinical Global Impression Scale, Sympson-Angus Rating Scale, Barnes Akathisia Rating Scale and followed up after 12 months. Successful switch after 4 weeks was achieved in 25 patients(clozapine 9(64.2%), risperidone 16(94.1%)). Overall, mean BPRS and CGI scores increased significantly. Successful maintenance after 12 months was achieved in 17 patients(clozapine 5(35.7%), risperidone 12(70.5%)). Overall, mean BPRS and CGI scores increased significantly too. Switching to olanzapine from other atypical antipsychotics is recommendable in chronic schizophrenia with treatment refractoriness and drug induced side effect.